Todd A. Sasser1 , Jens Waldeck2 , Andrew Van Praagh1 , W. Matthew Leevy2,3
1 Bruker Molecular Imaging, 44 Manning Rd, Billerica, MA 01821 USA;
2 Department of Chemistry and Biochemistry, University of Notre Dame, 236 Nieuwland Science Hall, Notre Dame, IN 46556 USA;
3 Notre Dame Integrated Imaging Facility, University of Notre Dame, Notre Dame, IN 46556 USA
Positron Emission Tomography (PET) has been successfully applied in neurological studies for a range of disease models including stroke/ischemia (Balsara et al., in Press, Sobrado et al., 2011, Pozo et al., 2008), Alzheimer’s disease (MartinMoreno et al., 2012), Parkinson’s disease (Fernández et al., 2011) and temporal brain activity (van der Veen et al., 2012). The Albira PET system has been proven to be an ideal platform for PET brain imaging studies, thanks to its combined high resolution and high sensitivity (Spinks et al., 2014), flexible imaging capacity and the capability to automatically fuse (optional) integrated computed tomography (CT). The brain volume-of-interest (VOI) tools, included as standard, as well as the kinetic modeling tools in PMOD (PMOD Technologies Ltd; Zurich, Switzerland; pmod.com/technologies/index.html) can be extended with dedicated modules such as pBRAIN for Alzheimer‘s disease modeling.
